ArticleRadiology. Imaging cancer2020
Utility of T2-weighted MRI to Differentiate Adrenal Metastases from Lipid-Poor Adrenal Adenomas.
Article in Radiology. Imaging cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic performance of radiomics in adrenal masses: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Habitat-radiomics combining multichannel 2.5D deep learning for differentiating adrenal adenomas from metastases using automatic segmentation: a multicenter study.Frontiers in endocrinology · 2026Article
- Differentiation of Fat-poor and Atypical Adrenal Adenomas from Metastases: MRI-based Radiomic, Radiologic, and Radiomic-radiologic Machine Learning Models.Current medical imaging · 2026Article
- Washed up: the end of an era for adrenal incidentaloma CT.Insights into imaging · 2025Review
- The Value of PET/CT-Based Radiomics in Predicting Adrenal Metastases in Patients with Cancer.Diagnostics (Basel, Switzerland) · 2025Article
- Feasibility of extracellular volume fraction derived from single-phase spectral CT for differentiating between adrenal metastases and adenomas.Abdominal radiology (New York) · 2025Article
- Review
- Diagnostic performance of magnetic resonance imaging features to differentiate adrenal pheochromocytoma from adrenal tumors with positive biochemical testing results.BMC medical imaging · 2024Article
- Primary Cardiac Intimal Sarcoma: Multi-Layered Strategy and Core Role ofDiagnostics (Basel, Switzerland) · 2024Review
- Comparative Analysis of FSE T2 Weighted, Chemical Shift and Dynamic Contrast-Enhanced MR Imaging in the Characterization of Adrenal Masses Based on Qualitative and Quantitative Parameters.Sisli Etfal Hastanesi tip bulteni · 2024Article
- An Integrated CT and MRI Imaging Model to Differentiate between Adrenal Adenomas and Pheochromocytomas.Cancers · 2023Article
- Article
- Differentiation of adrenal adenomas from adrenal metastases in single-phased staging dual-energy CT and radiomics.Diagnostic and interventional radiology (Ankara, Turkey) · 2022Article
- Dual-energy spectral detector computed tomography differential diagnosis of adrenal adenoma and pheochromocytoma: Changes in the energy level curve, a phenomenon caused by lipid components?Frontiers in endocrinology · 2022Article
- Qualitative Heterogeneous Signal Drop on Chemical Shift (CS) MR Imaging: Correlative Quantitative Analysis between CS Signal Intensity Index and Contrast Washout Parameters Using T1-Weighted Sequences.Tomography (Ann Arbor, Mich.) · 2021Article
- Hepatocellular carcinoma: metastatic pathways and extra-hepatic findings.Abdominal radiology (New York) · 2021Review
- Novel Insights of T2-Weighted Imaging: Significance for Discriminating Lung Cancer from Benign Pulmonary Nodules and Masses.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate T2-weighted MRI features to differentiate adrenal metastases from lipid-poor adenomas. Materials and Methods: With institutional review board approval, this study retrospectively compared 40 consecutive patients (mean age, 66 years ± 10 [standard deviation]) with metastases to 23 patients (mean age, 60 years ± 15) with lipid-poor adenomas at 1.5- and 3-T MRI between June 2016 and March 2019. A blinded radiologist measured T2-weighted signal intensity (SI) ratio (SI Results: Subjectively, T2-weighted SI ( Conclusion: Logistic regression models combining T2-weighted SI and T2-weighted heterogeneity can differentiate metastases from lipid-poor adenomas. Validation of these preliminary results is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.